Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.
Featured Video
European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision
CIDP
Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.
The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements
Jeffrey A. Allen, MD
University of Minnesota
12:15 MIN
CIDP
Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.
Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
15:18 MIN
CIDP
GBS
Learn more about the importance of understanding typical and atypical presentations of GBS, including features of clinically distinct variants and subtypes, proper diagnosis, and initiation of appropriate treatment.
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
NOW PLAYING
09:29
Fatigue in CIDP
Engage in a presentation on the comparison between active and remission disease states in CIDP.
NOW PLAYING
12:15
The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength...
Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.
NOW PLAYING
15:18
Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
Learn more about the importance of understanding typical and atypical presentations of GBS, including features of clinically distinct variants and subtypes, proper diagnosis, and initiation of appropriate treatment.
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.
Carol L. Koski, MD
GBS/CIDP Foundation International
Carol L. Koski, MD
GBS/CIDP Foundation International
CIDP
GBS
Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International.
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
CIDP
Peter Van den Bergh is Professor of Neurology at the Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Jeffrey A. Allen, MD
University of Minnesota
Jeffrey A. Allen, MD
University of Minnesota
CIDP
MMN
Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.
What is Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?